Has Marie Delvalle-Mahoney, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,967 in general payments to Marie Delvalle-Mahoney, MD across 100 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marie Delvalle-Mahoney, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marie Delvalle-Mahoney, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marie Delvalle-Mahoney, MD

Internal Medicine · Slidell, LANPI 1972645786

Payments from drug & device makers

$1,967in general payments, 2019–2025

Across 100 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$373
Pfizer$329
Lilly USA, LLC$209
GSK$140
Inspire Medical Systems, Inc.$111
Dexcom, Inc.$92
plus $712 from 18 others

What the payments were for

Food & beverage$1,967100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	22	$373
Pfizer	18	$329
Lilly USA, LLC	7	$209
GSK	7	$140
Inspire Medical Systems, Inc.	1	$111
Dexcom, Inc.	4	$92
AbbVie	4	$81
Amgen	5	$76
Abbott	3	$71
AstraZeneca	4	$67
Esperion Therapeutics, Inc.	3	$48
Sanofi-aventis U.S. LLC	3	$44
Ironwood Pharmaceuticals, Inc	2	$44
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$37
Lundbeck LLC	2	$35
Boehringer Ingelheim	2	$30
Astellas Pharma US Inc	2	$29
Exact Sciences	2	$29
Takeda Pharmaceuticals U.S.A., Inc.	2	$29
Alnylam Pharmaceuticals Inc.	1	$21
Sumitomo Pharma America, Inc.	1	$20
Biohaven Pharmaceuticals, Inc.	1	$18
Asensus Surgical, Inc.	1	$17
Halozyme Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZEPBOUND$112
Inspire$111

How this compares

$1,967 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024

$88,754

Medicare patients

243

Services billed

1,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	155	$185,200
OzempicSemaglutide	122	$121,073
JardianceEmpagliflozin	77	$82,643
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	94	$76,013
EliquisApixaban	74	$59,781
JanuviaSitagliptin Phosphate	42	$47,627
TrulicityDulaglutide	34	$45,941
FarxigaDapagliflozin Propanediol	21	$31,034
RybelsusSemaglutide	24	$29,235
ProliaDenosumab	16	$27,617
XareltoRivaroxaban	29	$25,970
EntrestoSacubitril/Valsartan	18	$21,090
MyrbetriqMirabegron	23	$14,982
GemtesaVibegron	12	$13,748
Breztri AerosphereBudesonide/Glycopyr/Formoterol	16	$9,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity	$209	$231,141189 claims
Novo NordiskOzempic, Rybelsus	$373	$150,308146 claims
Boehringer IngelheimJardiance	$30	$82,64377 claims
GSKTrelegy Ellipta, Breo Ellipta	$140	$81,851106 claims
PfizerEliquis, Premarin	$329	$62,32185 claims
AstraZenecaFarxiga, Breztri Aerosphere	$67	$40,82737 claims
AmgenProlia	$76	$27,61716 claims
Astellas Pharma US IncMyrbetriq	$29	$14,98223 claims
Sumitomo Pharma America, Inc.Gemtesa	$20	$13,74812 claims
AbbVieSynthroid, Creon	$81	$11,075141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.